Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves First RSV vaccine for adults under 60
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.
CDC Lowers Age for First Pneumococcal Vaccine
US CDC Recommends Expanding Pneumococcal Vaccines to Adults Aged 50-64
The U.S. Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines to adults between 50-64 years to protect against pneumococcal disease. The agency's earlier recommendation for vaccination was for adults 65 years or older and children younger than 5,
US CDC advisers recommend expanding pneumococcal vaccine to adults aged 50-64
(Reuters) -Advisers to the Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines to adults between 50-64 years to protect against pneumococcal disease. The CDC currently recommends all children younger than 5 and all adults 65 years or older get vaccinated for the disease.
CDC Lowers Age for First Pneumococcal Vaccine to 50
The CDC on Wednesday lowered the recommended age for a first pneumococcal vaccine to 50, down from 65. The vaccine protects against a range of bacterial illnesses such as pneumoni
2d
on MSN
Q&A on the 2024-2025 COVID-19 Vaccines
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...
1d
Does the updated Pfizer COVID-19 vaccine protect against the XEC variant?
Watch Toronto's #1 morning show for the latest news, weather and traffic from across the GTA.
14h
A Pfight At Pfizer
There's some rumbling going on within Pfizer's investment community, as an activist hedge fund says that the company's ...
6d
FDA asks Texas court to shut down COVID-19 vaccine records lawsuit
The U.S. Food and Drug Administration has asked a federal judge in Texas to throw out a public records lawsuit related to ...
FiercePharma
9d
GSK takes mRNA patent fight to Moderna, suing over vaccines for COVID and RSV
Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...
infectiousdiseaseadvisor.com
1d
COVID-19 2024 to 2025 Vaccines, for Everyone 6 Months and Older, Target New Strains
COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.
2d
on MSN
Is the system letting down people who were harmed by Covid vaccines?
Platelets are cells that help your blood clot, and it was so unusual to see blood clots combined with low platelet levels, ...
8d
Northwestern sues Moderna for patent infringement over COVID-19 vaccines
Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused ...
BioPharma Dive
2d
Starboard makes case for change at Pfizer, citing research, M&A missteps
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
Hosted on MSN
9d
What to Expect From Pfizer's Q3 2024 Earnings Report
Valued at a market cap of $164.8 billion, Pfizer Inc. (PFE) discovers, manufactures, distributes, and markets medicines and ...
BioSpace
8d
Novavax Shares Slide as FDA Pauses COVID/Flu Vaccine Candidates
The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.
cidrap.umn
1d
Can COVID vaccines induce mucosal immunity? Two studies offer conflicting findings
Experiments with mice that received repeated mRNA vaccination showed evidence of neutralizing antibody–producing cells in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback